Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Approval Delays For Standard NMEs Caused Primarily By “Safety Issues” – FDA

Executive Summary

FDA is citing "safety issues" as the primary reason for approval delays for standard new molecular entities in 2000 and 2001 in its 12002 Report to the Nation

You may also be interested in...



Manufacturing Reviews In Second-Cycle NDAs To Be Streamlined In FDA Pilot

FDA hopes to streamline chemistry, manufacturing and controls review in resubmitted NDAs and supplemental applications through several pilot programs

Manufacturing Reviews In Second-Cycle NDAs To Be Streamlined In FDA Pilot

FDA hopes to streamline chemistry, manufacturing and controls review in resubmitted NDAs and supplemental applications through several pilot programs

FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total

FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly

Related Content

UsernamePublicRestriction

Register

PS041797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel